# NEXGEL (NXGL) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/NXGL
## Company Profile
- Ticker: NXGL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.17 USD
- Market cap: 5305142.955 USD
- Last updated: 2026-10-05
## Business Overview
### Hydrogel and Healthcare Products Company
NEXGEL develops, manufactures, and commercializes healthcare, beauty, and over-the-counter products. Its core expertise is in soft, high-water-content hydrogels used in wound care, skin care, consumer health, and other applications requiring gentle contact with the body.
### Cross-Linked Hydrogel Platform
The company has more than two decades of experience manufacturing electron-beam cross-linked hydrogels. This process supports hydrogel products with customizable adhesion, moisture, cooling, and delivery characteristics for both proprietary brands and third-party customers.
### Consumer and Wound-Care Brands
NEXGEL's branded portfolio includes SilverSeal, Hexagels, Turfguard, Kenkoderm, and Silly George. The products span wound dressings, blister and skin protection, dermatology, and beauty applications, allowing the company to address both professional healthcare channels and direct-to-consumer markets.
### BioNX Surgical
BioNX Surgical expands NEXGEL into regenerative surgical products following the acquisition of assets from Celularity. The division is integrating sales relationships and transferring manufacturing capabilities with Sequence Life Science to support tissue-product availability and expansion into hospitals and ambulatory surgery centers.
### Regenerative Eye Health and Aesthetics
BioNX Regenerative Eye Health & Aesthetics is a commercial initiative focused on ocular and aesthetic applications. It incorporates exclusively licensed products from Sequence and extends the company's regenerative-medicine strategy into physician-directed specialty markets.
### Contract Manufacturing
Alongside its owned brands, NEXGEL manufactures hydrogel products for established consumer healthcare companies. This contract-manufacturing activity uses the same materials and production expertise that support its internal healthcare and consumer portfolio.
## Why The Stock Is Moving

As of Oct 5, 2026, NXGL closed down 2.30% at $0.1700. No new same-company headline was identified in the current news window.

## Recent News
- 2026-09-23 13:29 EST — [NEXGEL Announces Dial-In Details for Investor Update Call](https://biopharmsignal.com/news/NXGL/nexgel-announces-dial-in-details-for-investor-update-call-29d0d8fa) — Source: NEXGEL
- 2026-09-16 13:29 EST — [NEXGEL Announces Date for Investor Update Call](https://biopharmsignal.com/news/NXGL/nexgel-announces-date-for-investor-update-call-abcb358a) — Source: NEXGEL
- 2026-08-20 20:05 EST — [NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE](https://biopharmsignal.com/news/NXGL/nexgel-announces-leadership-transition-and-strategic-review-initiative-a396c7ca) — Source: NEXGEL
- 2026-08-17 12:00 EST — [NEXGEL Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NXGL/nexgel-reports-second-quarter-2026-financial-results-720c0a60) — Source: NEXGEL
- 2026-06-04 13:00 EST — [NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th](https://biopharmsignal.com/news/NXGL/nexgel-to-present-at-planet-microcap-conference-las-vegas-on-june-16th-18th) — Source: NEXGEL